论文部分内容阅读
目的:探讨环氧合酶-2(COX-2)和膜结合型前列腺素E2合成酶1(mPGES-1)在肾透明细胞癌组织中的表达及临床意义。方法:采用免疫组化SP法分别检测49例肾透明细胞癌组织标本和21例正常肾组织标本中COX-2和mPGES-1的表达。结果:COX-2在正常肾组织中的阳性表达率为4.8%,在肾透明细胞癌组织中的阳性表达率为53.1%(P<0.05);mPGES-1在正常肾组织中的阳性表达率为4.8%,在肾透明细胞癌组织中的阳性表达率为40.8%(P<0.05);COX-2和mPGES-1的高表达均与肾透明细胞癌的病理分级和临床分期无相关性(P>0.05);COX-2和mPGES-1在肾透明细胞癌中的表达呈正相关(P<0.05),r=0.5。结论:COX-2和mPGES-1在肾透明细胞癌发生及发展过程中共同发挥重要作用;COX-2和mPGES-1可能成为肾透明细胞癌新的治疗靶点。
Objective: To investigate the expression and clinical significance of cyclooxygenase-2 (COX-2) and membrane-bound prostaglandin E2 synthase 1 (mPGES-1) in renal clear cell carcinoma. Methods: The expressions of COX-2 and mPGES-1 in 49 cases of renal clear cell carcinoma and 21 cases of normal renal tissue were detected by immunohistochemical SP method. Results: The positive expression rate of COX-2 in normal renal tissues was 4.8% and in renal clear cell carcinoma tissues was 53.1% (P <0.05). The positive expression rate of mPGES-1 in normal renal tissues (4.8%). The positive expression rate of COX-2 and mPGES-1 in renal clear cell carcinoma tissue was 40.8% (P <0.05). The high expression of COX-2 and mPGES-1 had no correlation with the pathological grade and clinical stage of renal clear cell carcinoma P> 0.05). The expression of COX-2 and mPGES-1 in renal clear cell carcinoma was positively correlated (P <0.05), r = 0.5. CONCLUSION: COX-2 and mPGES-1 play an important role in the occurrence and development of renal clear cell carcinoma. COX-2 and mPGES-1 may be new therapeutic targets for renal clear cell carcinoma.